Mucoadhesive Polymers for Enhancing Retention in Ocular Drug Delivery

Progress in Adhesion and Adhesives

Volumn , Issue , 2015, Pages 451-484

  Khare, Anubha ^a   Grover, Kanchan ^a   Pawar, Pravin ^a   Singh, Inderbir ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

Gene delivery; Human mucin genes; Mucoadhesive polymers; Ocular drug delivery

Indexed keywords

BIOCHEMISTRY; CHITOSAN; GENE TRANSFER; GENES; TARGETED DRUG DELIVERY; VISCOSITY;

CONTROLLED RELEASE; DRUG DELIVERY SYSTEM; GENE DELIVERY; MUCOADHESIVE POLYMERS; OCULAR DRUG DELIVERY; PENETRATION ABILITY; PENETRATION ENHANCERS; SYNTHETIC POLYMERS;

CONTROLLED DRUG DELIVERY;

EID: 84955063600     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119162346.ch12     Document Type: Chapter

References (186)

1. Y. Sultane, R. Jain, and M. Aqil, Review of ocular drug delivery. Curr. Drug Deliv. 3, 207-217 (2006).
2. J.D. Henderer and C.J. Raprano, Ocular pharmacology, in: Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th edition, L.L. Brunton, J.S. Lazo, and K.L. Parker, (Eds.), pp. 1707-1737, McGraw-Hill, New York (2005).
3. U. Arto, Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58, 1131-1135 (2006).
4. N.M. Davies, Biopharmaceutical considerations in topical ocular drug delivery. Clin. Expl. Pharmacol. Physiol. 27, 558-562 (2000).
5. J.W Shell, Ocular drug delivery systems-A review. Cutaneous Ocular Toxicol. 1, 49-63 (1982).
6. S. Ding, Recent developments in ophthalmic drug delivery. Pharm Sci. Technol Today 1, 328-335 (1998).
7. C. Losa, P. Calvo, E. Castro, J.L. Vila-Jato, and M.J. Alonso, Improvement of ocular penetration of amikacin sulphate by association to poly (butylcyanoacrylate) nanoparticles. J. Pharm. Pharmacol. 43, 548-552 (1991).
8. C. Losa, L. Marchal-Heussler, F. Orallo, J.L. Vila-Jato, and M.J. Alonso, Design of new formulations for topical ocular administration: Polymeric nanocapsules containing metipranolol. Pharm. Res. 10, 80-87 (1993).
9. A.M. De Campos, A. Sanchez, R. Gref, P. Calvo, and M.J. Alonso, The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur. J. Pharm. Sci. 20, 73-81 (2003).
10. O. Dudinski, B.C. Finnin, and B.L. Reed, Acceptability of thickened eye drops to human subjects. Curr. Ther. Res. 33, 322-337 (1983).
11. C. Marriott and N.P. Gregory, Mucus physiology and pathology, in: Bioadhesive Drug Delivery Systems, V. Gurny (Ed.), pp. 1-24, CRC Press, Boca Raton, FL (1990).
12. S. Roy, K. Pal, A. Anis, K. Pramanik, and B. Prabhakar. Polymers in mucoadhesive drug delivery system: A brief note. Designed Monomers Polymers 12, 483-495 (2009).
13. I. Singh and V. Rana, Enhancement of mucoadhesive property of polymers for drug delivery applications: A critical review. Rev. Adhesion Adhesives 1, 271-290 (2013).
14. B.A. Nichols, M.L. Chiappino, and C.R. Dawson, Demonstration of the mucous layer of the tear film by electron microscopy. Invest. Ophthalmol Visual Sci. 26, 464-473 (1985).
15. I.K. Gipson, M. Yankauckas, S.J. Spurr-Michaud, A.S. Tisdale, and W. Rinehar, Characteristics of a glycoprotein in the ocular surface glycocalyx. Invest. Ophthalmol. Visual Sci. 33, 218-227 (1992).
16. J.L. Greaves and C.G. Wilson, Treatment of diseases of the eye with mucoadhesive delivery systems. Adv. DrugDeliv Rev. 11, 349-383 (1993).
17. J.C. Robinson, Ocular anatomy and physiology relevant to ocular drug delivery, in: Ophthalmic Drug Delivery Systems, A.K. Mitra (Ed.), pp. 29-57, Marcel Dekker, New York (1993).
18. C.M. Lehr, Lectin-mediated drug delivery: The second generation of bioadhesives. J. Controlled Release. 65, 19-29 (2000).
19. G.P. Andrew, T.P. Laverty, and D.S. Jones, Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 71, 505-518 (2009).
20. T. Inatomi, S. Spurr-Michaud, A.S. Tisdale, and I.K. Gipson, Human corneal and conjunctival epithelia express MUC1 mucin. Invest. Ophthalmol. Visual Sci. 36, 1818-1827 (1995).
21. T. Inatomi, S. Spurr-Michaud, A.S. Tisdale, and I.K. Gipson, Expression of secretory mucin genes by human conjunctival epithelia. Invest. Ophthalmol. Visual Sci. 37, 1684-1692 (1996).
22. M. Berry, R.B. Ellingham, and A.P. Corfield, Polydispersity of normal human conjunctival mucins. Invest. Ophthalmol. Visual Sci. 37, 2559-2571 (1996).
23. M.M. Jumblatt, R.W McKenzie, and J.E. Jumblatt, MUC5AC mucin is a component of the human precorneal tear film. Invest. Ophthalmol. Visual Sci. 40, 43-49 (1999).
24. R.W. McKenzie, J.E. Jumblatt, and M.M. Jumblatt, Quantification of MUC2 and MUC5AC transcripts in human conjunctiva. Invest. Ophthamol. Visual Sci. 41, 703-708 (2000).
25. M.M. Jumblatt, R.W. McKenzie, P.S. Steele, C.G. Emberts, and J.E. Jumblatt, MUC7 expression in the human lacrimal gland and conjunctiva. Cornea. 22, 41-45 (2003).
26. P. Argueso, M. Balaram, S. Spurr-Michaud, H.T. Keutmann, M.R. Dana, and I.K. Gipson. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest. Ophthalmol. Visual Sci. 43, 1004-1011 (2002).
27. P. Argueso, S. Spurr-Michaud, C.L. Russo, H.T. Keutmann, M.R. Dana, and . MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest. Ophthalmol. Visual Sci. 44, 2487-2495 (2003).
28. H.S. Ching, H. Park, P. Kelly, and J.R. Robinson, Bioadhesive polymers as platforms for oralcontrolled drug delivery. II. Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J Pharm Sci. 74, 399-405 (1985).
29. J.W Lee, J.H. Park, and J.R. Robinson, Bioadhesive-based dosage forms: The next generation systems. J. Pharm. Sci. 89, 850-866 (2000).
30. X. Yang and J.R. Robinson, Bioadhesion in mucosal drug delivery, in: Biorelated Polymers and Gels, T. Okano (Ed.), Academic Press, London. (1998).
31. M.N. Kumar, R.A. Muzzarelli, C. Muzzarelli, H. Sashiwa, and A.J. Domb. Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 104, 6017-6084 (2004).
32. S.A. Agnihotri, N.N. Mallikarjuna, and T.M. Aminabhavi, Recent advances on chitosan-based micro and nanoparticles in drug delivery. J. Controlled Release. 100, 5-28 (2004).
33. O. Felt, P. Furrer, J.M. Mayer, B. Plazonnet, P. Buri, and R. Gurny, Topical use of chitosan in ophthalmology: Tolerance assessment and evaluation of precorneal retention. Int. J. Pharm. 180, 185-193 (1999).
34. P.K. Pawar and D.K. Majumdar, Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS Pharm. Sci. Technol. 7, 13 (2006).
35. M.S. Rathore and D.K. Majumdar, Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS. Pharm Sci. Technol. 7, 57 (2006).
36. V. Dodane and V.D. Vilivalam, Pharmaceutical applications of chitosan. Pharm. Sci. Technol. Today 1, 246-253 (1998).
37. A.M. De Campos, A. Sanchez, and M.J. Alonso, Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Int. J. Pharm. 224, 159-168 (2001).
38. C.M. Lehr, J.A. Bouwstra, E.H. Schacht, and H.E. Junginger, In vitro evaluation of mucoadhesive properties of chitosan and other natural polymers. Int. J. Pharm. 78, 43-48 (1992).
39. J.G. LeHoux and F. Grondin, Some effects of chitosan on liver function in the rat. Endocrinology. 132, 1078-1084 (1993).
40. S.R. Jameela, T.V. Kumary, A.V. Lal, and A. Jayakrishna, Progesterone-loaded chitosan microspheres: A long acting biodegradable controlled delivery system. J. Controlled Release. 52, 17-24 (1998).
41. K. Bowman and W. Leong, Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomedicine. 1, 117-128 (2006).
42. A.K. Singla and M. Chawla, Chitosan: Some pharmaceutical and biological aspects- an update. J. Pharm. Pharmacol. 53, 1047-1067(2001).
43. K. Nagpal, S.K. Singh, and D.N. Mishra, Chitosan nanoparticles: A promising system in novel drug delivery. Chem. Pharm Bull (Tokyo). 58, 1423-1430 (2010).
44. H. Yi, L.Q. Wu, WE. Bentley, R. Ghodssi, G.W. Rubloff, J.N. Culver, and G.F. Payne, Biofabrication with chitosan. Biomacromolecules. 6, 2882-2894 (2005).
45. A. Bernkop-Schnurch, D. Guggi, and Y. Pinter, Thiolated chitosans: Development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J. Controlled Release. 94, 177-186 (2004).
46. M.J. Alonso and A. Sanchez, The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol. 55, 1451-1463 (2003).
47. G. Sandri, M.C. Bonferoni, E.H. Gokce, F. Ferrari, S. Rossi. M. Patrini, and C. Caramella, Chitosan-associated SLN: In vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J. Microencapsulation. 27, 735-476 (2010).
48. H. Refai and R. Tag, Development and characterization of sponge like acyclovir ocular minitablets. Drug. Deliv. 18, 38-45 (2011).
49. K.M. Sanjay, S. Chopra, S. Talegoankar, and K. Kohli, Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimization and in vitro characterization. Eur. J. Pharm. Biopharm. 68, 513-525 (2008).
50. R.C. Nagarwal, R. Kumar, and J.K. Pandit, Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro characterization and in vivo study in rabbit eye. Eur. J. Pharm. Sci. 47, 678-685 (2012).
51. W. Chaiyasan, S.P. Srinivas, and W. Tivaboonchai, Mucoadhesive chitosan-dextran sulfate nanoparticles for sustained drug delivery to the ocular surface. J. Ocular. Pharmacol. Therapy. 29, 200-207 (2013).
52. P. Suphiya, M. Moutushy, S. Krishnakumar, and S.K. Sahoo, Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta. Biomaterialia. 6, 3120-3131 (2010).
53. K. Kesvan, S. Kant, P.N. Singh, and J.K. Pandit, Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: In vitro and in vivo evaluation. Curr. Eye. Res. 38, 342-352 (2013).
54. H.R. Lin and P.C. Chang, Novel Pluronic-chitosan micelle as an ocular delivery system. J. Biomed. Mater. Res. B. 101, 689-699 (2013).
55. Z. Xuan, S. Meiqin, T. Shaoheng, L. Wang, and X. Liang, Synthesis of thiolated chitosan and preparation of nanoparticles with sodium alginate for ocular drug delivery. Mol. Vision. 18, 1973-1982 (2012).
56. A.A. Mahmoud, G.S. El-Feky, R. Kamel, and G. E. A. Awad, Chitosan/sulfobutylether- P-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int. J. Pharm. 413, 229-236 (2011).
57. F. Kratz, Albumin as a drug carrier: Design of prodrug conjugates and nanoparticles. J. Controlled Release. 132, 171-183 (2008).
58. U. Kragh-Hansen, Structure and ligand binding properties of human serum albumin. Danish. Med. Bull. 37, 57-84 (1990).
59. R.S. Sudha and G. Deshpande, Albumin microspheres as an ocular delivery system for Pilocarpine nitrate. Ind. J. Pharm. Sci. 70, 193-197 (2008).
60. M. Yun, E.B. Michael, and T. Dolores, Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol. Vision. 13, 746-757 (2007).
61. B. Vasudevan, T.L. Simpson, and J.G. Sivak, Regional variation in the refractive-index of the bovine and human cornea. Optometry Visual Sci. 85, 977-981 (2008).
62. H. Kim, S.B. Robinson, and K.G. Csaky, Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm. Res. 26, 329-337 (2009).
63. R.T. Addo, A. Siddig, and R. Siwale, Formulation, characterization and testing of tetracaine hydrochloride loaded albumin-chitosan microparticles for ocular drug delivery. J. Microencapsulation. 27, 95-104 (2010).
64. O. Smidsrod and G. Skjak-Braek, Alginate as immobilization matrix for cells. Trends in Biotechnology. 8, 71-78 (1990).
65. R. Russo, M. Malinconico, and G. Santagata, Effect of cross-linking with calcium ions on the physical properties of alginate films. Biomacromolecules. 8, 3193-3197 (2007).
66. K. Kesvan, G. Nath, and J.K. Pandit, Preparation and in vitro antibacterial evaluation of gatifloxacin mucoadhesive gellan system. Daru. 18, 237-246 (2010).
67. K.L. Mittal, The role of the interface in adhesion phenomena, Polym. Eng. Sci., 17, 467-473 (1977).
68. N. Ahuja, V. Saini, V.K. Bishnoi, A. Garg, M. Hisoria, and J. Sharma, Formulation and evaluation of diclofenac sodium gel by using natural polymer. Rasayan. J. Chem. 1, 564-66 (2008).
69. C. Trinquand, J.P. Romanet, J.P. Nordmann, J.C. Dascotte, J.L. George, P. Lesure, R.C. Allen, A.L. Robin, D. Long, G.D. Novack, J.C. Lue, and G. Kaplan, Efficacite et tolerance du carteolol 1% liberation prolongee une fois par jour. J. Fr. Ophthalmol. 26, 131-136 (2003).
70. P.E. Jansson and B. Lindberg, Structural studies of gellan gum, an extracellular polysaccharide elaborated by Pseudomonas elodea. Carbohydrate. Res. 124, 135-139 (1983).
71. M.S. Kuo, A.J. Mort, and A. Dell, Identification and location of L-glycerate, an unusual acyl substituent in gellan gum. Carbohydrate. Res. 156, 173-187 (1986).
72. D. Lobas, S. Schumpe, and W.D. Deckwer, The production of gellan exopolysaccharide with Sphingomonas paucimobilis E2 (DSM 6314). Appl. Microbiol. Biotechnol. 37, 411-415 (1992).
73. D.E. Pszczola, Gellan gum wins IFT's food technology industrial achievement award. Food. Technol. 47, 94-96 (1993).
74. J. Balasubramaniam, S. Kant, and J.K. Pandit, In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. Acta. Pharm. 53, 251-261 (2003).
75. H.M. El-Laithy, D.I. Nesseem, A.A. El-Adly, and M. Shoukry, Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation. Arch. Pharm. Res. 34, 1663-1678 (2011).
76. J.Q. Shen, Y. Gan, L. Gan, C.L. Zhu, and J.B. Zhu, Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil. Yao Xue Xue Bao. 45, 120-125 (2010).
77. Y.D. Sanzgiri, S. Maschi, V. Crescenzi, L. Callegaro, E.M. Topp, and V.J. Stella,Gellan-based systems for ophthalmic sustained delivery of methylprednisolone. J. Controlled Release. 26, 195-201(1993).
78. Y. Liu, J. Liu, X. Zhang, and R. Zhang, In situ gelling Gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS. Pharm Sci. Technol. 11, 610-620 (2010).
79. E.F. Rosenlund, The intraocular pressure-lowering effect of timolol in gel-forming solution. Acta. Ophthalmol. Scand. 74, 160-162 (1996).
80. A.H. Shedden, J. Laurence, A. Barrish, and T.V. Olah, Plasma timolol concentrations of timolol maleate: Timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc. Ophthalmol. 103, 73-79 (2001).
81. S.A. Altaf, K. Yu, J. Parasrampuria, and D.R. Friend, Guar gum-based sustained release. Diltiazem. Pharm. Res. 15, 1196-1201 (1998).
82. M.A. Zirnsak, D.V. Boger, and V. Tirtaatmadja, Study of shear and dynamic rheological properties of xanthan gum solution in viscous solvents. J. Rheology. 43, 627-650 (1999).
83. J.L. Zatz and S. Knapp, Viscosity of xanthan gum solution at low shear rates. J. Pharm. Sci. 73, 468-471 (1984).
84. J. Ceulemans, I. Vinckier, and A. Ludwig, The use of xanthan gum in ophthalmic dosage form: Rheological characterisation of the interaction with mucin. J. Pharm Sci. 91, 1117-1127 (2002).
85. G. Meseguer, P. Buri, B. Plazonnet, A. Rozier, and R. Gurny, Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J. Ocul. Pharmacol. Therapy. 12, 481-488 (1996).
86. S.M. Al-Saidan, Y.S.R. Krishnaiah, S.S. Patro, and V. Satyanaryana, In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. AAPS. Pharm Sci. Technol. 6, 14-21 (2005).
87. N.I. Dure and A.H. Erum, Physiological and pharmaceutical properties of guar gum derivatives. Rep. Opin. 2, 77-83 (2010).
88. P. Khullar, R.K. Khar, and S.P. Agarwal, Evaluation of guar gum in the release of sustained release matrix tablets. Drug. Dev. Ind. Pharm. 24, 1095-1099 (1998).
89. T.R. Bhardwaj, M. Kanwar, R. Lal, and A. Gupta, Natural gums and modified natural gums as sustained release carriers. Drug. Dev. Ind. Pham. 26, 1025-1038 (2000).
90. J.H. Guo, G.W Skinner, W.W. Harcum, and RE. Barnum, Pharmaceutical applications of naturally occurring water soluble polymers. Pham. Sci. Technol. Today. 1, 254-261 (1988).
91. A. Matheson, Your patient has dry eye: What treatments are available. http://www.ocularsolu- tions.com
92. G.N. Foulks, Clinical evaluation of the efficacy of PEG/PG lubricant eye drops with gelling agent (HP-Guar) for the relief of the signs and symptoms of dry eye disease: A review. Drugs Today. (Barcelona) 43, 887-896 (2007).
93. H.G. Garg and C.A. Hales, Chemistry and Biology of Hyaluronan. Istedition., pp. 1-21, Elsevier, Oxford (2004).
94. G. Kogan, L. Soltes, R. Stern, and P Gemeiner, Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol. Lett. 29, 17-25 (2006).
95. P Gribbon, B.C. Heng, and T.E. Hardingham, The analysis of intermolecular interactions in concentrated hyaluronan solutions suggests no evidence for chain-chain association. Biochem. J. 350, 329-335 (2000).
96. F. Guillaumi, P Furrer, O. Felt-Baeyens, B.L. Fuhlendorff, and S. Nymand, Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications. Invest. Ophthalmol. Visual Sci. 43, 3409-3415(2002).
97. V.P. De Luise and S.W. Peterson, The use of topical Healon tears in the management of refractory dry-eye syndrome. Ann. Ophthalmol. 16, 823-824 (1984).
98. F. Baudouin, F. Brignole, and B. Dupas, Reduction in keratitis and CD44 expression in dry eye patients treated with a unique 0.18% sodium hyaluronate solution. Invest Ophthalmol Visual Sci. 42, S32 (2001).
99. R. Vogel, R.S. Crockett, N. Oden, T.W. Laliberte, and L. Molina, Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution. Am. J. Ophthalmol. 149, 594-601 (2010).
100. M.F. Saettone, P Chetoni, M.T. Torracca, S. Burgalassi, and B. Giannaccini, Evaluation of muco- adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pham. 51, 203-212 (1989).
101. Y. Xu, J.Z. Song, G.R. Pang, Z.J. Chen, J.J. Zhang, and X.F. Lu, Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits. Zhonghua. Yan. Ke. Za. Zhi. 40, 87-89 (2004).
102. S.F. Bernatchez, C. Tabatabay, and R. Gurny, Sodium hyaluronate 0.25% used as a vehicle increases the bio availability of topically administered gentamicin. Graefes Arch. Clin. Expl. Ophthalmol. 231, 157-161 (1993).
103. R.C. Rowe, PJ. Sheskey, and S.C. Owen, (Eds), Handbook of Pharmaceutical Excipients, 5th edition, Pharmaceutical Press, London, UK (2006).
104. Remington: The Science and Practice of Pharmacy, 21st edition, PP. Gerbino (Ed), pp. 1318-1349, Lippincott,Williams & Wilkins, Philadelphia (2005).
105. C. Rochas and M. Rinaudo, Activity coefficients of counterions and conformation in kappa- Carrageenan systems. Biopolymers. 19, 1675-1687 (1980).
106. I.D. Rupenthal, C.R. Green, and R.G. Alany, Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physiochemical characterization and in vitro release. Int J Pharm. 411, 69-77 (2011).
107. M. Saettone, E. Burgalassi, P Boldrini, P Bianchini, and G. Luciani, Ophthalmic solutions vis- cosified with tamarind seed polysaccharide, US Patent 6056950A, assigned to. Farmigea SPA (May 2. 2000).
108. L.L. Mannucci, I. Fregona, and D. Gennaro, Use of a new lachrymal substitute (TS polysaccharide) in contactology. J. Med. Contacology. Low. Vision. 1, 6-9 (2000).
109. E. Ghelardi, A. Tavanti, P. Davini, and F. Celandroni, A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of Rufloxacin in topical treatment of experimental bacterial keratitis. Antimicrobial Agents. Chemother. 48, 3396-3401 (2004).
110. M. Rolando and C. Valente, Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: Results of a clinical study. BMC Ophthalmol. 7, 5:1-8 (2007).
111. P. Versura, V. Profazio, N. Balducci, and E.C. Campos, Efficacy of two-month treatment with Xiloial eyedrops for discomfort from disposable soft contact lenses. Clin. Ophthlamol. 4, 10351041 (2010).
112. G. Uccello- Barretta, S. Nazzi, Y. Zambito, G. Di Colo, F. Balzano, and M. Sanso, Synergistic interaction between TS-polysaccharide and hyaluronic acid: Implications in the formulation of eye drops. Int. J. Pharm. 395, 122-131 (2010).
113. A.D. Prete and M. Sanso, Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid. EP2197456B1 (Febrary 23, 2010).
114. H. Kaura, M. Ahuja, S. Kumar, and N. Dilbaghia, Carboxymethyl tamarind kernel polysaccharide nanoparticles for ophthalmic drug delivery. Int. J. Biol. Macromol. 50, 833-839 (2012).
115. G. Uccello-Barretta, S. Nazzi, F. Balzano, and M. Sanso, A nuclear magnetic resonance approach to the comparison of mucoadhesive properties of polysaccharides for ophthalmic uses. Int. J. Pharm. 406, 78-83 (2011).
116. G. Uccello-Barretta, F. Balzano, L. Vanni, and M. Sanso, Mucoadhesive properties of tamarind- seed polysaccharide/hyaluronic acid mixtures: A nuclear magnetic resonance spectroscopy investigation. Carbohydrate Polym. 91, 568-72 (2013).
117. S. Burgalassi, N. Nicosia, D. Monti, and G. Falcone, Larch arabinogalactan for dry eye protection and treatment of corneal lesions: Investigation on rabbits. J. Ocular Pharmacol. Therapy. 23, 541-550 (2007).
118. S.S. Leung and J.R. Robinson The contribution of anionic polymer structural features to mucoadhesion. J. Controlled Release. 5, 223-231 (1988).
119. M.M. Patel, J.D. Smart, T. G. Nevell, R.J. Ewen and P J. Eaton, Mucin/poly (acrylic acid) interactions: A spectroscopic investigation of mucoadhesion. Biomacromolecules. 4, 1184-1190 (2003).
120. Z. Degim and I.W Kellaway, An investigation of the interfacial interaction between poly (acrylic acid) and glycoprotein. Int. J. Pharm. 175, 9-16 (1998).
121. M. Oescher and S. Keipert, Polyacrylic acid/polyvinylpyrrolidone biopolymeric systems: I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome. Eur. J. Pharm. Biopharm. 47, 113-118 (1999).
122. K. Marner, RM. Moller, M. Dillon, E.R. Pedersen, P. Armitage, and M. Hills, Viscous Carbomer eye drops in patients with dry eye. Acta. Ophthalmol. Scand. 74, 249-252 (1996).
123. E.J. Michael, J.M. Paul, and B. Mike, Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optometry. Visual Sci. 85, 750-757 (2008).
124. Q. Xiao, Y. Hu, F. Chen, and X. Chen, A comparative assessment of the efficacy of Carbomer gel and carboxymethyl cellulose containing artificial tears in dry eyes. J. Huazhong. Univ. Sci. Technol. 28, 592-595 (2008).
125. C. Wu, H. Qi, and W Chen, Preparation and evaluation of a Carbopol/ HPMC based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi. 127, 183-191 (2007).
126. H. Wu, Z. Liu, J. Peng, L. Li, N. Li, J. Li, and H. Pan, Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int. J. Pharm. 410, 31-40 (2011).
127. K. Kesavan, S. Kant, PN. Singh, and J.K. Pandit, Effect of hydroxypropyl-ß-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel. Curr. Eye. Res. 36, 918-929 (2011).
128. K. P Mukesh, C. Gulshan, and P Kamla, Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: Ex-vivo transcorneal permeation, corneal toxicity and irritation testing. Drug. Dev. Ind. Pharm. 39, 780-790 (2013).
129. PK. Deshmukh and S.G. Gattani, In vitro and in vivo consideration of novel environmentally responsive ophthalmic drug delivery system. Pharm. Dev. Technol. 18, 950-956 (2013).
130. G.H. Hsiue, J.A. Guu, and C.C. Cheng, Poly (2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine. Biomaterials. 22, 1763-1769 (2001).
131. A.U. Canan, Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (Azasite") solution in the treatment of ocular infections. Clin. Ophthalmol. 5, 801-809 (2011).
132. R. Pignatello, C. Bucolo, and G. Puglisi, Ocular tolerability of Eudragit RS 100R and RL 100R nanosuspensions as carriers for ophthalmic controlled drug delivery. J. Pharm. Sci. 91, 2636-2641 (2002).
133. U.A. Shinde, J.N. Shete, H.A. Nair, and K.H. Singh, Eudragit RL100 based microspheres for ocular administration of azelastine hydrochloride. J. Microencapsulation. 29, 511-519 (2012).
134. H.K. Ibrahim, I.S. El-Leithy, and A.A. Makky, Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone biotherapy. Mol. Pharmaceutics. 7, 576-585 (2010).
135. R. Pignatello, N.K. Ricupero, C. Bucolo, F. Maugeri, A. Maltese, and G. Puglisi, Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of Cloricromene. AAPS. Pharm Sci. Technol. 7, E27 (2006).
136. G. Khurana, S. Arora, and PK. Pawar, Ocular insert for sustained delivery of gatifloxacin sesqui- hydrate: Preparation and evaluations. Int. J. Pharm. Investig. 2, 70-77 (2012).
137. PK. Pawar, R. Katara, and D.K. Majumdar, Design and evaluation of moxifloxacin hydrochloride ocular inserts. Acta Pharm. 62, 93-104 (2012).
138. K.PR. Chowdary, and Y. Shrinivasrao, Mucoadhesive drug delivery systems: A review of current status. Indian Drugs. 37, 400-406 (2000).
139. Z. Liu, J. Li, S. Nie, H. Liu, P Ding, and W Pan, Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int. J. Pharm. 315, 12-17 (2006).
140. S. Mandal, M.K. Thimmasetty, G. Prabhushankar, and M. Geetha, Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. Int. J. Pharm. Investig. 2, 78-82 (2012).
141. A. Prinz, C. Fennes, W. Buehl, and O. Findl, Efficacy of ophthalmic viscosurgical devices in maintaining corneal epithelial hydration and clarity: In vitro assessment. J. Cataract. Refract. Surgery. 38, 2154-2159 (2012).
142. Y.A. Chen, N. Hirnschall, and O. Findl, Comparison of corneal wetting properties of viscous eye lubricant and balanced salt solution to maintain optical clarity during cataract surgery. J. Cataract. Refract. Surgery. 37, 1806-1808 (2011).
143. C. Vijaya and G.K. Swetha, Ion-activated in situ gelling ophthalmic delivery systems of Azithromycin. Indian J. Pharm. Sci. 73, 615-620 (2011).
144. H. Wu, Z. Liu, J. Peng, L. Li, N. Li, J. Li, and H. Pan, Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int. J. Pharm. 410, 31-40 (2011).
145. K. Kesavan, S. Kant, PN. Singh, and J.K. Pandit, Effect of hydroxypropyl-ß-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel. Curr. Eye. Res. 36, 918-929 (2011).
146. K. P Mukesh, C. Gulshan, and P Kamla, Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: Ex-vivo transcorneal permeation, corneal toxicity and irritation testing. Drug. Dev. Ind. Pharm. 39, 780-790 (2013).
147. PK. Deshmukh and S.G. Gattani, In vitro and in vivo consideration of novel environmentally responsive ophthalmic drug delivery system. Pharm. Dev. Technol. 18, 950-956 (2013).
148. G.H. Hsiue, J.A. Guu, and C.C. Cheng, Poly (2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine. Biomaterials. 22, 1763-1769 (2001).
149. A.U. Canan, Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (Azasite") solution in the treatment of ocular infections. Clin. Ophthalmol. 5, 801-809 (2011).
150. R. Pignatello, C. Bucolo, and G. Puglisi, Ocular tolerability of Eudragit RS 100R and RL 100R nanosuspensions as carriers for ophthalmic controlled drug delivery. J. Pharm. Sci. 91, 26362641 (2002).
151. U.A. Shinde, J.N. Shete, H.A. Nair, and K.H. Singh, Eudragit RL100 based microspheres for ocular administration of azelastine hydrochloride. J. Microencapsulation. 29, 511-519 (2012).
152. H.K. Ibrahim, I.S. El-Leithy, and A.A. Makky, Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone biotherapy. Mol. Pharmaceutics. 7, 576-585 (2010).
153. R. Pignatello, N.K. Ricupero, C. Bucolo, F. Maugeri, A. Maltese, and G. Puglisi, Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of Cloricromene. AAPS. Pharm Sci. Technol. 7, E27 (2006).
154. G. Khurana, S. Arora, and PK. Pawar, Ocular insert for sustained delivery of gatifloxacin sesqui- hydrate: Preparation and evaluations. Int. J. Pharm. Investig. 2, 70-77 (2012).
155. PK. Pawar, R. Katara, and D.K. Majumdar, Design and evaluation of moxifloxacin hydrochloride ocular inserts. Acta Pharm. 62, 93-104 (2012).
156. K.PR. Chowdary, and Y. Shrinivasrao, Mucoadhesive drug delivery systems: A review of current status. Indian Drugs. 37, 400-406 (2000).
157. Z. Liu, J. Li, S. Nie, H. Liu, P Ding, and W Pan, Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int. J. Pharm. 315, 12-17 (2006).
158. S. Mandal, M.K. Thimmasetty, G. Prabhushankar, and M. Geetha, Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. Int. J. Pharm. Investig. 2, 78-82 (2012).
159. A. Prinz, C. Fennes, W. Buehl, and O. Findl, Efficacy of ophthalmic viscosurgical devices in maintaining corneal epithelial hydration and clarity: In vitro assessment. J. Cataract. Refract. Surgery. 38, 2154-2159 (2012).
160. Y.A. Chen, N. Hirnschall, and O. Findl, Comparison of corneal wetting properties of viscous eye lubricant and balanced salt solution to maintain optical clarity during cataract surgery. J. Cataract. Refract. Surgery. 37, 1806-1808 (2011).
161. C. Vijaya and G.K. Swetha, Ion-activated in situ gelling ophthalmic delivery systems of Azithromycin. Indian J. Pharm. Sci. 73, 615-620 (2011).
162. G. Abdelbary, Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm. Dev. Technol. 1, 44-56 (2011).
163. M.M. Mehanna, H.A. Elmaradny, and M.W Samaha, Mucoadhesive liposomes as ocular delivery system: Physical, microbiological, and in vivo assessment. Drug. Dev. Ind. Pharm. 1, 108-118 (2010).
164. J. Shen, Y. Wang, Q. Ping, Y. Xiao, and X. Huang, Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Controlled Release. 137, 217-223 (2009).
165. R.M. Byrro, G.D.O. Fulgenico, and A.J. Da Silva- Cunha, Determination of ofloxacin in tear by HPLC-ESI-MS/MS method: Comparison of ophthalmic drug release between a new mucoadhesive chitosan film and a convential eye drop formulation in rabbit model. J. Pharm. Biomed. Anal. 70, 544-548 (2012).
166. G.O. Fulgencio, F.A. Viana, R.R. Ribeiro, M.I. Yoshida, A.G. Faraco, A.S. Cunha-Junior, New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: In vivo evaluation. J. Ocular Pharmacol. Therapy. 4, 350-358 (2012).
167. G. Di Colo, S. Burgalassi, P. Chetoni, M.P. Fiaschi, Y. Zambito, and M.F. Saettone, Gel- forming erodible inserts for ocular controlled delivery of ofloxacin. Int. J. Pharm. 215, 101-111 (2001).
168. P.A. Campochiaro, Q.D. Nguyen, G. Hafiz, S.M. Shah, S. Bloom, D.M. Brown, M. Busquets, and T. Ciulla, Aqueous levels of fluocinolone acetonide after administration of fluocinolone aceton- ide inserts or fluocinolone acetonide implants. Ophthalmology. 120, 583-587 (2013).
169. T. Nguyen and R. Latkany, Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye. Clin. Ophthlamol. 5, 587-591 (2011).
170. M.A. Babizhayev, Current ocular drug delivery challenges for N-acetylcarnosine: Novel routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent. Patent Drug. Deliv. Formul. 3, 229-265 (2009).
171. M. De la Fuente, B. Seijo, and M.J. Alonso, Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Therapy. 15, 668-676 (2008).
172. S. Suri and R. Banerjee, In vitro evaluation of in situ gels as short term vitreous substitutes. J. Biomed. Mater. Res. A. 79, 650-664 (2006).
173. J.L. Ubels, D.P Clousing, T.A. Van Haitsma, B.S. Hong, P Stauffer, B. Asgharian, and D. Meadows, Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl- guar as a gelling agent. Curr. Eye. Res. 28, 437-444 (2004).
174. M. Karakelle and M.R. Brunstedt, Carrageenan viscoelastics for ocular surgery. US Patent, No. 7060297B2 (2006).
175. S. Burgalassi, P Chetoni, L. Panichi, E. Boldrini, and M.F. Saettone, Xyloglucan as a novel vehicle for timolol: Pharmacokinetics and pressure lowering activity in rabbits. J. Ocular. Pharmacol. Therapy. 16, 497-509 (2000).
176. T. Tammelin, A. Paananen, and M. Osterberg, Hemicelluloses at interfaces: Some aspects of the interactions, in: The Nanoscience and Technology of Renewable Biomaterials, 1st edition, O.J Rojas and L.A Lucia (Eds.), pp. 149-172, Wiley Publishing (2009).
177. A. Ludwig, The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug. Dev. Rev. 57, 1595-1639 (2005).
178. N. Sanders, L. Peeters, I. Lentacker, I. Demeester, and S.C. De Smedt, Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J. Controlled Release. 122, 226-235 (2007).
179. A. Venkatesh, M. Shan, F. Langellotto, and G. Gao, Retinal gene delivery by rAAV and DNA electroporation. Curr Protocol in Microbiol. 28, 14D.4.1-14D.4.32 (2013).
180. G. Puras, J. Zarate, M. Aceves, A. Murua, and A.R. Dhaz, Low molecular weight oligochitosans for non-viral retinal gene therapy. Euro. J. Pham. Biopharm. 83, 131-140 (2013).
181. S. Alqawlaq, J.T. Huzil, M. V. Ivanova, and M. Foldvari, Challenges in neuroprotective nanomedicine development:Progess towards noninvasive gene therapy of glaucoma. Nanomedicine. 7, 1067-1083 (2012).
182. A. Tandon. A. Sharma, J.T. Rodier, A.M. Klibanov, and F.G. Rieger, BMP7 Gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. Plos One. 8, 434 (2013).
183. M. Jiang, Li Gan, C. Zhu, Y. Dong, J. Liu, and Y. Gan, Cationic core shell liponanoparticles for ocular gene delivery. Biomaterials. 33, 7621-7630 (2012).
184. C.M. Adeyeye, L.V Davis, and K.U. Kotreka, In-situ gel ophthalmic drug delivery system of estradiol for prevention of cataracts. US Patent, No. 20110082128 A1 (2011).
185. E. Matsumoto, Y. Nishina, and K. Haruna, Ophthalmic composition containing alginic acid and salt thereof. US Patent, No. 8501822 B2 (2013).
186. A.D. Prete and M. Sanso, Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid. US Patent, No.20100279981A1 (2010).